论文部分内容阅读
目的探究和分析干扰素α-2b、低剂量阿糖胞苷及羟基脲联合治疗慢性粒细胞白血病(CML)的临床疗效。方法 56例慢性粒细胞白血病患者,随机分为观察组和对照组,每组28例。对照组采用羟基服联合干扰素α-2b治疗,观察组采用干扰素α-2b、低剂量阿糖胞苷及羟基服联合治疗,对比分析两组患者的临床疗效。结果观察组患者疗效显著优于对照组(P<0.05);两组均出现轻微不良反应,有效治疗后消失。结论干扰素α-2b、低剂量阿糖胞苷及羟基脲联合治疗慢性粒细胞白血病的临床效果显著,值得临床推广应用。
Objective To explore and analyze the clinical efficacy of interferon alfa-2b, low-dose cytarabine and hydroxyurea in the treatment of chronic myelogenous leukemia (CML). Methods 56 patients with chronic myeloid leukemia were randomly divided into observation group and control group, 28 cases in each group. The control group was treated with hydroxypropyl and interferon alfa-2b, and the observation group was treated with interferon alpha-2b, low-dose cytarabine, and hydroxybutanoxacin, and the clinical efficacy of the two groups was compared and analyzed. Results The curative effect of the observation group was significantly better than that of the control group (P<0.05). Mild adverse reactions occurred in both groups and disappeared after effective treatment. Conclusion The clinical effect of interferon alfa-2b, low-dose cytarabine and hydroxyurea in the treatment of chronic myelogenous leukemia is significant and worthy of clinical application.